CPI-818 for T-Cell Lymphoma
Trial Summary
What is the purpose of this trial?
This trial is testing a new pill called CPI-818 for patients with T-cell lymphoma that hasn't responded to other treatments. The pill works by blocking a protein that helps cancer cells grow.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop all current medications, but you cannot take strong inhibitors or inducers of CYP3A (a type of enzyme that affects drug metabolism). It's best to discuss your current medications with the trial team.
What makes the drug CPI-818 unique for treating T-cell lymphoma?
CPI-818 is a novel treatment for T-cell lymphoma that may offer a different approach compared to existing therapies, although specific details about its mechanism or administration are not provided in the available research. T-cell lymphomas, particularly those involving CD8+ cells, are rare and not well-characterized, suggesting that CPI-818 could be addressing a gap in treatment options for these specific subtypes.12345
Research Team
Suresh Mahabhashyam, MD, MPH
Principal Investigator
Corvus Pharmaceuticals
Eligibility Criteria
This trial is for adults over 18 with T-cell lymphoma that's come back or hasn't responded to at least two standard treatments, or where only one treatment exists. They should have measurable disease signs, good organ function, and be fairly active (ECOG status of 0 or 1). People who've had certain transplants, use strong CYP3A affecting drugs, have primary immunodeficiency, recent serious infections, are pregnant/lactating women or those planning pregnancy can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants will receive CPI-818 capsule, orally, twice per day at an assigned dose, until disease progression, complete response or remission for more than 2 months, or if dose is determined to be unsafe.
Dose Expansion
Participants with different T-cell lymphoma sub-types will receive CPI-818 capsules at the specific dose selected from the Dose Escalation phase.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- CPI-818
Find a Clinic Near You
Who Is Running the Clinical Trial?
Corvus Pharmaceuticals, Inc.
Lead Sponsor